Intersect ENT Inc

Intersect ENT — Technical Presentation (October 2017)

21 slides from Intersect ENT's technical presentation, Oct 10, 2017

  1. Slide 1: The role of corticosteroid-eluting stents for the management of recurrent nasal polyposis

    The role of corticosteroid-eluting stents for the management of recurrent nasal polyposis Robert C. Kern MD George A. Sisson Professor of Otolaryngology Chairman, Department of Otolaryngology-Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago, Illinois

  2. Slide 2: Disclosures

    Disclosures Received research grants from NIH (Core PI) and Intersect ENT (Co-PI) Received consulting fees from 480 Biomedical, Genentech, Sanofi, NUIG and GSK The steroid-releasing implant discussed in this presentation is not approved by the US FDA and has not received CE Mark. The implant is limi

  3. Slide 3: Chronic Rhinosinusitis with Nasal Polyps

    Chronic Rhinosinusitis with Nasal Polyps The multi-factorial pathophysiology of CRSwNP prevents long-term effectiveness of any single treatment option Medical management includes systemic and intranasal corticosteroids (INCS) Surgical treatment relieves blockage and improves ventilation o 40% recurr

  4. Slide 4: Investigational In-Office Therapy Designed for Nasal Polyps in CRS Patients

    Investigational In-Office Therapy Designed for Nasal Polyps in CRS Patients An investigational corticosteroid-eluting, bioabsorbable sinus implant Designed to deliver 1350 mcg of mometasone furoate directly to the ethmoid sinus mucosa over approximately 90 days In-office placement under topical anes

  5. Slide 5: The RESOLVE II Study

    The RESOLVE II Study Randomized, sham-controlled, double-blind, phase 3, pivotal trial To evaluate the safety and efficacy of the investigational sinus implant in adults with CRSwNP, who were indicated for repeat surgery to treat moderate-to-severe, medically-refractory symptoms of nasal obstruction

  6. Slide 6: Patients

    Patients CRSwNP Prior ESS, including bilateral total ethmoidectomy Indicated for revision ESS Persistent moderate-to-severe symptoms of nasal obstruction/congestion score ³ 2 (scale 0 to 3) on 5 out of 7 days despite ongoing INCS and recent course of high-dose steroids Post-nasal discharge, facial p

  7. Slide 7: Methods

    Methods N=300 34 clinical sites across the US Randomized 2:1 Treatment Implants + MFNS Baseline Screening Day 14 Day 30 Day 60 Day 90 Procedure Control Sham + MFNS eDiary Treatment group in-office bilateral implant placement in the ethmoid sinuses Control group in-office bilateral sham procedure All

  8. Slide 8: Methods

    Methods Treatment Screening Implants + MFNS Baseline Day 60 Day 90 Reviewer Procedure Day 14 Day 30 Implant Panel grading Panel Control removal grading Sham + MFNS grading eDiary Screening NP grade confirmed by an independent reviewer Patients blinded to treatment assignment and masked/ear muffed du

  9. Slide 9: Assessment

    Assessment Patient-reported outcomes Endoscopic examination Adverse events The steroid-eluting sinus implant discussed here is not approved by the US FDA and has not received CE Mark. The product is an investigational drug not currently available for sale in any geography. The steroid releasing impl

  10. Slide 10: Efficacy Endpoints

    Efficacy Endpoints Co-primary endpoints: Nasal obstruction/congestion score (scale 0-3), CFBL to day 30 Bilateral polyp grade (scale 0-8), CFBL to day 90 (an independent, blinded panel) 5 Prespecified secondary endpoints adjusted for multiplicity: Proportion of patients still indicated for repeat ES

  11. Slide 11: Indication for Repeat ESS Criteria

    Indication for Repeat ESS Criteria SCREENING & DAY 90 Is the patient indicated for repeat ESS? Nasal polyp grade (on each side) Nasal Obstruction/Congestion score 0 1 2 ³ 3 1 (mild) NoNo No No 2 (moderate) NoNo Yes Yes 3 (severe) NoNo Yes Yes 11

  12. Slide 12: Baseline Demographics & Clinical Characteristics

    Baseline Demographics & Clinical Characteristics Variable Treatment Control Total no. of patients 20199 Age (y)50.5±12.947.9±12.4 Male subjects63.2%56.6% Number of prior ESS 141.3%41.4% ³ 258.7%58.6% Allergic rhinitis77.1%79.8% Asthma73.6%*61.6% AERD14.9%17.2% Nasal obstruction/congestion score (sca

  13. Slide 13: Co-Primary Efficacy Results

    Co-Primary Efficacy Results Nasal Obstruction/Congestion Bilateral Polyp Grade (eDiary) (Independent Panel) 0 0 30 90 Day Day to to baseline -0.5 Baseline -0.5 from Change from p=0.0073 Change -1 -1 p=0.0074 Treatment Control Met both co-primary efficacy objectives The steroid-eluting sinus implant

  14. Slide 14: Met Prespecified Secondary Endpoints

    Met 4 out of 5 Prespecified Secondary Endpoints Reduction in proportion of patients still indicated for repeat ESS at day 90 (p=0.0004) Reduction in percent ethmoid obstruction, CFBL to day 90 (panel) (p=0.0007) Reduction in nasal obstruction/congestion, CFBL to day 90 (p=0.0248) Improvement in sens

  15. Slide 15: Reduction in Proportion of Patients Still Indicated for Repeat ESS at Day 90

    Reduction in Proportion of Patients Still Indicated for Repeat ESS at Day 90 100% 90% .0004 80% p=0 -37% 70% 60% -61% 63% 50% 40% 30% 39% 20% 10% 0% Treatment Control The steroid-eluting sinus implant discussed here is not approved by the US FDA and has not received CE Mark. The product is an invest

  16. Slide 16: Reduction in Bilateral Polyp Grade by Investigators

    Reduction in Bilateral Polyp Grade by Investigators Study Day 0 14 30 45 60 75 90 SEM) 0 ± -0.5 (mean Control -1 baseline -1.5 * from * -2 * Treatment* Change -2.5 * p-value < 0.05 * p<0.0001 The steroid-eluting sinus implant discussed here is not approved by the US FDA and has not received CE Mark.

  17. Slide 17: Reduction in Nasal Obstruction/Congestion Score

    Reduction in Nasal Obstruction/Congestion Score Study Day 0 14 30 45 60 75 90 SEM) 0 ± (mean -0.5 Control baseline -1 * * from * Treatment Change -1.5 * p-value < 0.05 * p<0.05 The steroid-eluting sinus implant discussed here is not approved by the US FDA and has not received CE Mark. The product is

  18. Slide 18: Proportion of Patients Experiencing Improvement

    Proportion of Patients Experiencing Improvement Variable Treatment Control P-value OR (95% CI) Nasal obstruction/congestion score 44.2% 25.8% 0.0022 1.72 (1.18, 2.49) ³ 1.0-point reduction to day 30 Bilateral polyp grade (panel) 36.4% 22.7% 0.0179 1.61 (1.06, 2.42) ³ 1.0-point reduction BL to day 90

  19. Slide 19: Investigational Sinus Implant for In-Office Treatment of Nasal Polyps

    Investigational Sinus Implant for In-Office Treatment of Nasal Polyps The steroid-eluting sinus implant discussed here is not approved by the US FDA and has not received CE Mark. The product is an investigational drug not currently available for sale in any geography. The steroid releasing implants

  20. Slide 20: Safety

    Safety 4 Serious adverse events in 3 patients (2 treatment and 1 control), but only 1 (0.5%) implant-related (epistaxis) Similar incidence of adverse events between treatment and control groups (45.3% vs. 37.4%) The steroid-eluting sinus implant discussed here is not approved by the US FDA and has n

  21. Slide 21: Conclusion

    Conclusion The RESOLVE II study following in-office placement of the corticosteroid-releasing implants in patients with recurrent nasal polyps met both co-primary objectives: o Reduction in nasal obstruction/congestion and o Reduction in bilateral polyp grade The study also showed a reduction in the

Intersect ENT — Technical Presentation (October 2017) on 6ix